Table 3.
Studies reporting CD112 as a diagnostic and prognostic biomarker
| Reference | First Author | Year | Type of cancer | Sample size | comments |
|---|---|---|---|---|---|
| [68] | Miao et al. | 2013 | Gallbladder cancer |
46 SC/ASCa 80 ACb |
CD112 expression was associated with aggressiveness and poor prognosis |
| [44, 73] |
Daniel et al. Huang et al. |
2021 2014 |
Liver cancer | 159 | Low CD112 expression was associated with poor OS of patients, but contradicted by evidence from preclinical studies |
| [80] | Karabulut et al. | 2015 | Colorectal carcinoma (CRC) | 140 | Serum CD112 levels have a diagnostic value and high levels correlated with an adverse prognostic impact on PFS patients with early-stage |
| [83] | Liang et al. | 2015 | Pancreatic Ductal Adenocarcinomas | 106 | CD112 expression was associated with the progression and poor prognosis |
| [84] | Izumi et al. | 2015 | Pancreatic adenocarcinoma | 49 | CD112 was not associated with overall survival, but higher CD112 expression correlated with worse histological grade. |
| [77] | Stamm et al. | 2018 | AML | 429c | High CD112 expression correlated with shorter overall survival |
| [76] | Erturk et al. | 2019 | Lung cancer | 74 | Serum CD112 expression level was a reliable diagnostic but not prognostic or predictive biomarker. |
| [81] | Bekes et al. | 2019 | Ovarian cancer | 60 | CD112 expression supported tumor cell adhesion, leading to growth and lymph node metastasis. |
aSC/ASC: squamous cell/adenosquamous carcinoma
b AC: adenocarcinomas
cincluding 139 AML patients enrolled in the AMLSG 07–04 study of the German-Austrian Study Group (NCT00151242) [78] and 290 AML patients in the GEO database (GEO accession GSE6891) [79]